Literature DB >> 36185615

The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.

Rosa Shapiro-Thompson1, Sarah K Fineberg1.   

Abstract

Purpose of review: a)This review paper describes the state of prescribing practice in Borderline Personality Disorder (BPD), wherein medications are prescribed far more than either evidence or practice guideline would recommend. First, we describe the frequencies of medication use and polypharmacy in people with BPD. Recent findings: b)In subsequent sections, we elaborate two main categories of factors that lead to overmedication of people with BPD: the interpersonally mediated and the structural. We consider interpersonally mediated factors to arise from communications of patients in distress and the well-meaning efforts of their prescribers to provide relief for certain overwhelming affective states. We are particularly focused on patterns of countertransference in prescribing that are directly linked to specific aspects of BPD pathology. We consider structural factors to arise from the complexities of medical and medicolegal systems and the contemporary patterns of financing medical care; we postulate that these complexities often compel prescribers to start medications, with associated disincentives for decreasing or discontinuing those medications over time. Summary: c)More research is needed to understand how to best use medications in BPD, for example in targeted combination with psychotherapeutic and psychosocial interventions. However, current practice often departs markedly from the evidence. We recommend the dissemination of accessible, generalist BPD-treatment models in outpatient and inpatient practice; increased early detection of BPD; and increased diagnostic disclosure. We also recommend for individual providers and systems to implement prospective treatment plans that draw from BPD-specific psychosocial models. This approach can employ tiers of interventions to minimize reactive prescribing by anticipating high affect and offering BPD patients steadily empathic evidence-supported care.

Entities:  

Keywords:  Borderline Personality Disorder; Good Psychiatric Management; countertransference; deprescribing; psychopharmacology; psychotropics

Year:  2022        PMID: 36185615      PMCID: PMC9524237          DOI: 10.1007/s40501-021-00255-x

Source DB:  PubMed          Journal:  Curr Treat Options Psychiatry


  55 in total

1.  Treatment histories of borderline inpatients.

Authors:  M C Zanarini; F R Frankenburg; G S Khera; J Bleichmar
Journal:  Compr Psychiatry       Date:  2001 Mar-Apr       Impact factor: 3.735

2.  Drug allergies among patients with borderline personality symptomatology.

Authors:  R A Sansone; J Gentile; R J Markert
Journal:  Gen Hosp Psychiatry       Date:  2000 Jul-Aug       Impact factor: 3.238

3.  Overview of current and future research and clinical directions for drug discontinuation: psychological, traditional and professional obstacles to deprescribing.

Authors:  Doron Garfinkel
Journal:  Eur J Hosp Pharm       Date:  2017-01

4.  Rates of psychotropic medication use reported by borderline patients and axis II comparison subjects over 16 years of prospective follow-up.

Authors:  Mary C Zanarini; Frances R Frankenburg; D Bradford Reich; Alayna L Harned; Garrett M Fitzmaurice
Journal:  J Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.153

Review 5.  Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials.

Authors:  Klaus Lieb; Birgit Völlm; Gerta Rücker; Antje Timmer; Jutta M Stoffers
Journal:  Br J Psychiatry       Date:  2010-01       Impact factor: 9.319

6.  Controlling inpatient psychiatric utilization through managed care.

Authors:  T M Wickizer; D Lessler; K M Travis
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

Review 7.  Advances in interventions for families with a relative with a personality disorder diagnosis.

Authors:  Perry D Hoffman; Alan E Fruzzetti
Journal:  Curr Psychiatry Rep       Date:  2007-02       Impact factor: 8.081

8.  Dying Too Soon: Excess Mortality in Severe Mental Illness.

Authors:  Liselotte D de Mooij; Martijn Kikkert; Jan Theunissen; Aartjan T F Beekman; Lieuwe de Haan; Pim W R A Duurkoop; Henricus L Van; Jack J M Dekker
Journal:  Front Psychiatry       Date:  2019-12-06       Impact factor: 4.157

9.  Polypharmacy in psychiatry: a review.

Authors:  Sanjay Kukreja; Gurvinder Kalra; Nilesh Shah; Amresh Shrivastava
Journal:  Mens Sana Monogr       Date:  2013-01

10.  Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice.

Authors:  Charles Timäus; Miriam Meiser; Borwin Bandelow; Kirsten R Engel; Anne M Paschke; Jens Wiltfang; Dirk Wedekind
Journal:  BMC Psychiatry       Date:  2019-12-12       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.